Phase I/II trial of iPS-cell-derived dopaminergic cells for Parkinsons disease
www.nature.com
Nature, Published online: 16 April 2025; doi:10.1038/s41586-025-08700-0After transplantation into the brain of patients with Parkinsons disease, allogeneic dopaminergic progenitors derived from induced pluripotent stem cells survived, produced dopamine and did not form tumours, therefore suggesting safety and potential clinical benefits for Parkinsons disease.
0 Comments ·0 Shares ·11 Views ·0 Reviews